Webster Bank N. A. Decreases Position in Johnson & Johnson (NYSE:JNJ)

Webster Bank N. A. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 70,242 shares of the company’s stock after selling 494 shares during the quarter. Johnson & Johnson makes up 1.2% of Webster Bank N. A.’s portfolio, making the stock its 18th biggest holding. Webster Bank N. A.’s holdings in Johnson & Johnson were worth $9,088,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Billeaud Capital Management Inc. lifted its position in shares of Johnson & Johnson by 0.4% in the second quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after acquiring an additional 169 shares in the last quarter. Meeder Asset Management Inc. lifted its position in shares of Johnson & Johnson by 11.1% in the second quarter. Meeder Asset Management Inc. now owns 109,690 shares of the company’s stock valued at $15,277,000 after acquiring an additional 10,927 shares in the last quarter. Archford Capital Strategies LLC lifted its position in shares of Johnson & Johnson by 11.2% in the second quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock valued at $3,064,000 after acquiring an additional 2,211 shares in the last quarter. Marino Stram & Associates LLC lifted its position in shares of Johnson & Johnson by 1.2% in the second quarter. Marino Stram & Associates LLC now owns 32,199 shares of the company’s stock valued at $4,485,000 after acquiring an additional 380 shares in the last quarter. Finally, Palisades Hudson Asset Management L.P. lifted its position in shares of Johnson & Johnson by 42.6% in the second quarter. Palisades Hudson Asset Management L.P. now owns 2,241 shares of the company’s stock valued at $312,000 after acquiring an additional 669 shares in the last quarter. Institutional investors own 72.01% of the company’s stock.

Several analysts have recently issued reports on the company. Zacks Investment Research downgraded Johnson & Johnson from a “buy” rating to a “hold” rating and set a $139.00 price objective on the stock. in a research report on Thursday, July 18th. Bank of America restated a “hold” rating and issued a $150.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 16th. Raymond James reduced their price objective on Johnson & Johnson from $147.00 to $146.00 and set an “outperform” rating on the stock in a research report on Wednesday, July 17th. Credit Suisse Group set a $156.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research report on Tuesday, August 27th. Finally, Barclays assumed coverage on Johnson & Johnson in a research report on Friday, June 21st. They issued a “hold” rating and a $140.00 price objective on the stock. Five analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $150.60.

NYSE JNJ traded down $0.67 during trading hours on Thursday, hitting $131.33. 3,590,417 shares of the company’s stock were exchanged, compared to its average volume of 6,210,075. The business’s 50 day moving average is $129.81 and its 200-day moving average is $135.22. Johnson & Johnson has a 12-month low of $121.00 and a 12-month high of $148.99. The firm has a market capitalization of $341.46 billion, a P/E ratio of 16.06, a price-to-earnings-growth ratio of 2.19 and a beta of 0.69. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.04 and a current ratio of 1.33.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to the consensus estimate of $20.39 billion. During the same period in the prior year, the business posted $2.10 earnings per share. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. As a group, equities research analysts anticipate that Johnson & Johnson will post 8.6 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th were given a dividend of $0.95 per share. The ex-dividend date was Monday, August 26th. This represents a $3.80 annualized dividend and a yield of 2.89%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Understanding each part of a balance sheet

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.